Skip to main content

Table 1 Summary of efficacy data from randomized, controlled phase III trials of bevacizumab in advanced ovarian cancer

From: Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

Study (n) Regimen ORR (CR + PR), % Median PFS, months Median OS, months
[p value] [HR; p value] [HR; p value]
GOG-0218 [21] CP + placebo vs. CP + Bev vs. CP + Bev → Bev maintenance 10.3 vs. 11.2 vs. 14.1 39.3 vs. 38.7 vs. 39.7
(n = 1,873) [0.908; 0.16]a [1.036; 0.76]a
[0.717; < 0.001]b [0.915; 0.45]b
ICON7 [22, 23] CP vs. CP + Bev → Bev maintenance 48 vs. 67 17.4 vs. 19.8 Restricted mean survival time, months
(n = 1,528) [< 0.001] [0.87; 0.04] 44.6 vs. 44.5
OCEANS [24, 25] CG + placebo vs. CG + Bev 57.4 vs. 78.5 8.4 vs. 12.4 33.7c vs. 33.4c
(n = 484) [< 0.0001] [0.484; < 0.0001] [0.960; 0.736]
AURELIA [26, 27] CTx (PLD, P or Top) vs. CTx + Bev 12.6 vs. 30.9 3.4 vs. 6.7 13.3 vs. 16.6
(n = 361)   [0.001] [0.48; < 0.001] [0.85; 0.174]
  1. Bev = bevacizumab. C = carboplatin. CR = complete response. CTx = chemotherapy. G = gemcitabine. HR = hazard ratio. ORR = overall response rate. OS = overall survival. P = paclitaxel. PFS = progression-free survival. PLD = pegylated liposomal doxorubicin. PR = partial response. Top = topotecan.
  2. aCP + Bev vs. CP + placebo.
  3. bCP + Bev → Bev vs. CP + placebo.
  4. cInterim data.